INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Aerie Pharmaceuticals, Inc. (AERI) To Contact The Firm

News provided by

May 11, 2015, 03:46 ET

NEW YORK, May 11, 2015 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Aerie Pharmaceuticals, Inc. ("Aerie" or the "Company") (NASDAQ: AERI).

The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose material adverse information about the future prospects for its once-daily eye drop medication Rhopressa, designed to lower intraocular pressure ("IOP") in patients with glaucoma or ocular hypertension.

On April 23, 2015, Aerie issued a press release announcing the results of its first Phase 3 registration trial for Rhopressa. According to the press release, "[t]he trial did not meet its primary efficacy endpoint of demonstrating non-inferiority of IOP lowering for once-daily Rhopressa compared to twice-daily timolol, the most widely used comparator in registration trials for glaucoma."

Following this unexpected news, shares of Aerie's stock fell $22.52 per share, or over 63%, to close on April 24, 2015 at $12.87 per share.

Request more information now by clicking here: www.faruqilaw.com/AERI. There is no cost or obligation to you.

Take Action

If you invested in Aerie stock or options between August 6, 2014 and April 23, 2015 and would like to discuss your legal rights, visit www.faruqilaw.com/AERI. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected]. Faruqi & Faruqi, LLP also encourages anyone with information regarding Aerie's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
[email protected]
Telephone: (877) 247-4292 or (212) 983-9330

Logo - http://photos.prnewswire.com/prnh/20120119/MM38856LOGO

SOURCE Faruqi & Faruqi, LLP